Ide-Cel and KarMMa-3: Exploring the latest CAR T Data for Early R/R MM
The panelist discusses how the KarMMa-3 trial data demonstrated the superior efficacy of ide-cel vs standard regimens in triple-class exposed R/R MM, with a median progression-free survival of 13.3 vs 4.4 months and an overall response rate of 71% vs 42%. The favorable safety profile and significant survival benefit support ide-cel as a preferred option for third-line and greater treatment, particularly in patients with good performance status who can tolerate bridging therapy.
Video content above is prompted by the following:
- How does the latest data from the KarMMa-3 trial inform your decision to treat with idecabtagene vicleucel (ide-cel) for early R/R MM?
- How does the efficacy and safety data impact your selection of CAR T in the 3L setting?
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
